Cargando…

Improving the Lives of Patients with Alpha-1 Antitrypsin Deficiency

Alpha-1 Antitrypsin Deficiency (AATD) is a rare genetic condition that predisposes patients to lung and liver disease and is often underdiagnosed due to incomplete diagnosis of chronic obstructive pulmonary disease (COPD) and asthma. Improvements in physician awareness have been made, but better str...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sandhaus, Robert A, Strange, Charlie, Zanichelli, Andrea, Skålvoll, Karen, Koczulla, Andreas Rembert, Stockley, Robert A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7735792/ https://www.ncbi.nlm.nih.gov/pubmed/33328731 http://dx.doi.org/10.2147/COPD.S276773

Ejemplares similares

Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications
por: Chapman, Kenneth R, et al.
Publicado: (2018)

Alpha-1 Antitrypsin Deficiency: The Learning Goes On
por: Stockley, Robert. A.
Publicado: (2020)

Detection of alpha-1 antitrypsin deficiency: the past, present and future
por: Brantly, Mark, et al.
Publicado: (2020)

Pharmacokinetic comparability of Prolastin(®)-C to Prolastin(® )in alpha(1)-antitrypsin deficiency: a randomized study
por: Stocks, James M, et al.
Publicado: (2010)

Results from a large targeted screening program for alpha-1-antitrypsin deficiency: 2003 - 2015
por: Greulich, Timm, et al.
Publicado: (2016)

Monocytes and Macrophages in Alpha-1 Antitrypsin Deficiency
por: Belchamber, Kylie B R, et al.
Publicado: (2020)

How Can We Improve the Detection of Alpha1-Antitrypsin Deficiency?
por: Ferrarotti, Ilaria, et al.
Publicado: (2015)

Association of IREB2 and CHRNA3 polymorphisms with airflow obstruction in severe alpha-1 antitrypsin deficiency
por: Kim, Woo Jin, et al.
Publicado: (2012)

New Patient-Centric Approaches to the Management of Alpha-1 Antitrypsin Deficiency
por: Chorostowska-Wynimko, Joanna, et al.
Publicado: (2020)

Alpha-1 Antitrypsin Augmentation Therapy Improves Survival in Severely Deficient Patients with Predicted FEV1 Between 10% and 60%: A Retrospective Analysis of the NHLBI Alpha-1 Antitrypsin Deficiency Registry
por: Rahaghi, Franck F, et al.
Publicado: (2020)

An analysis of the degree of concordance among international guidelines regarding alpha-1 antitrypsin deficiency
por: Attaway, Amy, et al.
Publicado: (2019)

Environmental, occupational, and genetic risk factors for alpha-1 antitrypsin deficiency.
por: Sharp, Richard R, et al.
Publicado: (2003)

Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach
por: Stockley, Robert A, et al.
Publicado: (2013)

Anxiety and depression in patients with alpha-1 antitrypsin deficiency: current insights and impact on quality of life
por: Beiko, Tatsiana, et al.
Publicado: (2019)

Risk factors for symptom onset in PI*Z alpha-1 antitrypsin deficiency
por: Mayer, Annyce S, et al.
Publicado: (2006)

Is PiSS Alpha-1 Antitrypsin Deficiency Associated with Disease?
por: McGee, Dawn, et al.
Publicado: (2010)

Alpha 1 Antitrypsin Therapy in Patients with Alpha 1 Antitrypsin Deficiency: Perspectives from a Registry Study and Practical Considerations for Self-Administration During the COVID-19 Pandemic
por: Herth, Felix J F, et al.
Publicado: (2021)

The Distribution of Alpha-1 Antitrypsin Genotypes Between Patients with COPD/Emphysema, Asthma and Bronchiectasis
por: Veith, Martina, et al.
Publicado: (2020)

Does Augmentation with Alpha1-Antitrypsin Affect Neutrophil Extracellular Traps Formation?
por: Frenzel, Eileen, et al.
Publicado: (2012)

The prevalence of bronchiectasis in patients with alpha-1 antitrypsin deficiency: initial report of EARCO
por: Stockley, Robert A., et al.
Publicado: (2023)

COPD in individuals with the PiMZ alpha-1 antitrypsin genotype
por: Al Ashry, Haitham S., et al.
Publicado: (2017)

There is No Fast Track to Identify Fast Decliners in Alpha-1 Antitrypsin Deficiency by Spirometry: A Longitudinal Study of Repeated Measurements
por: Stockley, James A, et al.
Publicado: (2021)

The TNFalpha gene relates to clinical phenotype in alpha-1-antitrypsin deficiency
por: Wood, Alice M, et al.
Publicado: (2008)

Cardiovascular and musculskeletal co-morbidities in patients with alpha 1 antitrypsin deficiency
por: Duckers, James M, et al.
Publicado: (2010)

Free light chains: potential biomarker and predictor of mortality in alpha-1-antitrypsin deficiency and usual COPD
por: Hampson, Judith A., et al.
Publicado: (2016)

Krüppel-like zinc finger proteins in end-stage COPD lungs with and without severe alpha1-antitrypsin deficiency
por: Koczulla, A-Rembert, et al.
Publicado: (2012)

Detection of emphysema progression in alpha 1-antitrypsin deficiency using CT densitometry; Methodological advances
por: Parr, David G, et al.
Publicado: (2008)

Unique and shared systemic biomarkers for emphysema in Alpha-1 Antitrypsin deficiency and chronic obstructive pulmonary disease
por: Serban, K.A., et al.
Publicado: (2022)

Clinical considerations in individuals with α(1)-antitrypsin PI*SZ genotype
por: McElvaney, Gerard N., et al.
Publicado: (2020)

Relationship between frequency, length, and treatment outcome of exacerbations to baseline lung function and lung density in alpha-1 antitrypsin-deficient COPD
por: Vijayasaratha, Kesavaperumal, et al.
Publicado: (2012)

Therapy with Plasma Purified Alpha1-Antitrypsin (Prolastin(®)) Induces Time-Dependent Changes in Plasma Levels of MMP-9 and MPO
por: Koepke, Janine, et al.
Publicado: (2015)

Mineralization of alpha-1-antitrypsin inclusion bodies in Mmalton alpha-1-antitrypsin deficiency
por: Callea, Francesco, et al.
Publicado: (2018)

Individualized lung function trends in alpha-1-antitrypsin deficiency: a need for patience in order to provide patient centered management?
por: Stockley, Robert A, et al.
Publicado: (2016)

The parallel lives of alpha(1)-antitrypsin deficiency and pulmonary alveolar proteinosis
por: Trapnell, Bruce C, et al.
Publicado: (2013)

Gene therapy for alpha 1-antitrypsin deficiency with an oxidant-resistant human alpha 1-antitrypsin
por: Sosulski, Meredith L., et al.
Publicado: (2020)

Alpha-1 Antitrypsin as a Therapeutic Agent for Conditions not Associated with Alpha-1 Antitrypsin Deficiency
por: Wanner, Adam
Publicado: (2015)

Cardiovascular risk in patients with alpha-1-antitrypsin deficiency
por: Fähndrich, Sebastian, et al.
Publicado: (2017)

The prevalence of alpha-1 antitrypsin deficiency in Ireland
por: Carroll, Tomás P, et al.
Publicado: (2011)

The rs361525 polymorphism does not increase production of tumor necrosis factor alpha by monocytes from alpha-1 antitrypsin deficient subjects with chronic obstructive pulmonary disease - a pilot study
por: Gane, Jennie M., et al.
Publicado: (2015)

Alpha-1-antitrypsin antagonizes COVID-19: a review of the epidemiology, molecular mechanisms, and clinical evidence
por: Bai, Xiyuan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5qv1vo49k9vc7ljdg2k2njtbie